Ontology highlight
ABSTRACT:
SUBMITTER: Qi XS
PROVIDER: S-EPMC4427665 | biostudies-literature | 2015 May
REPOSITORIES: biostudies-literature
Qi Xing-Shun XS Guo Xiao-Zhong XZ Han Guo-Hong GH Li Hong-Yu HY Chen Jiang J
World journal of gastroenterology 20150501 18
The current standard treatment option for advanced hepatocellular carcinoma (HCC) is sorafenib, but its clinical benefit is modest. In spite of many attempts, few drugs can provide any significant improvement of survival as the first- or second-line therapy of choice in phase III randomized controlled trials. Recently, the subgroup analysis of a phase II randomized controlled trial has shown that tivantinib, a selective MET inhibitor, can significantly improve the overall survival in patients wi ...[more]